Fiera Capital Corp Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Fiera Capital Corp reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 350,329 shares of the biotechnology company’s stock after selling 9,667 shares during the period. Fiera Capital Corp owned approximately 0.37% of Sarepta Therapeutics worth $42,597,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in SRPT. Truist Financial Corp grew its stake in shares of Sarepta Therapeutics by 86.5% in the second quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock valued at $632,000 after buying an additional 1,857 shares in the last quarter. Blue Trust Inc. grew its position in Sarepta Therapeutics by 896.5% in the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 511 shares in the last quarter. Bank Pictet & Cie Europe AG raised its stake in shares of Sarepta Therapeutics by 27.7% during the third quarter. Bank Pictet & Cie Europe AG now owns 2,827 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 613 shares during the period. International Assets Investment Management LLC lifted its position in shares of Sarepta Therapeutics by 59,222.7% during the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 75,805 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the third quarter valued at $59,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 0.1 %

Sarepta Therapeutics stock opened at $109.81 on Thursday. The firm has a 50-day moving average price of $120.16 and a two-hundred day moving average price of $125.22. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Analyst Ratings Changes

Several research firms recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They set a “hold” rating and a $136.00 price target on the stock. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $176.77.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.